Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...
About a decade later, the U.S. Preventive Services Taskforce (USPSTF) issued updated guidelines recommending annual screening for lung cancer with low-dose CT for adults ages 50 to 80 years with a 20 ...
The FDA approved the first at-home test for cervical cancer screening, developed by Teal Health. In clinical trials, the accuracy of self-testing with Teal's wand matched that of a cancer screening ...
New Delhi: The most powerful weapon against cancer is not always a breakthrough drug; it is often a basic screening test done at the right time. Therefore, for millions of patients worldwide, the ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named ...